Vericel stock reacts to earnings beat and higher 2026 outlook
Vericel (VCEL) drew fresh attention after third quarter results showed revenue of US$85.37 million and net income of US$14.16 million, along with a raised full year 2026 revenue outlook.
The recent earnings beat and raised guidance have come alongside sharp price action, with Vericel's share price up 35.67% over the past week and 34.07% over the past month. This has contributed to a 53.38% year to date share price return and a 40.27% one year total shareholder return, which points to momentum building rather than fading.
Scan other fast moving healthcare opportunities by checking the hand picked 35 healthcare AI stocks that may reflect some of the momentum currently surrounding Vericel.
Vericel now has a profitable, growing business and a share price that has sprinted ahead in a matter of weeks. Do those recent gains still match what the fundamentals support, or has the valuation moved beyond what the story supports?
Most Popular Narrative: 9.8% Undervalued
Vericel last closed at $54.62, while the most followed narrative estimates a fair value of $60.57 based on a 7.59% discount rate. That gap rests on the idea that MACI and Burn Care can support much higher revenue and profitability than today.
Ongoing operational initiatives including the now approved Burlington manufacturing facility, automation and the approximately 30% MACI sales force expansion effective in 2026 are shifting from a transition year of fixed cost absorption toward the company's goal of around US$500m revenue and high 30% adjusted EBITDA margins by 2029. If achieved, this would improve net margins.
See why 9 investors see Vericel as 10% undervalued .
Result: Fair Value of $60.57 (UNDERVALUED)
Still, the Vericel narrative leans heavily on just a few therapies, and any slowdown in MACI adoption or setbacks in the Burlington ramp could quickly challenge those 2029 targets.
Find out about the key risks to this Vericel narrative .
Another View: Vericel looks expensive on earnings multiples
The SWS DCF model suggests Vericel is undervalued at $54.62, yet its P/E of 84x tells a different story. That ratio is far above the fair ratio of 24.6x, the US Biotechs average of 16.9x, and a peer average of 8.7x. Is the market simply paying up for the growth narrative?
See what the numbers say about this price, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
All this enthusiasm around Vericel raises a simple question for you: Are these expectations already in the price, or is there still a gap to close? To see why some investors remain optimistic about the setup, review the 2 key rewards .
Looking for more investment ideas beyond Vericel?
If Vericel has sharpened your focus, do not stop there. Broaden your watchlist and give yourself more options before the next big move catches you off guard.
-
Target reliable cash generators by scanning a list of solid balance sheet and fundamentals (24 results) that can handle shocks and still support long term plans.
-
Hunt for quality at a sensible entry point with a 40 high quality undervalued stocks that filters for strong fundamentals at prices some investors may be overlooking.
-
Stack potential income ideas by reviewing a 8 dividend fortresses that focuses on higher yielding companies with payouts that could matter for your returns.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VCEL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
